Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma

Journal of Pathology

Volumn 232, Issue 3, 2014, Pages 300-307

  Szuhai, Karoly ^a   De Jong, Daniëlle ^a   Leung, Wai Yi ^a   Fletcher, Christopher D M ^b   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

bLHL; MYOD1; next generation sequencing; rhabdomyosarcoma; soft tissue tumour; spindle cell; transactivating mutation

Indexed keywords

DESMIN; MITOCHONDRIAL DNA; MYOD1 PROTEIN; MYOGENIC FACTOR; MYOGENIC FACTOR 5; MYOGENIC FACTOR 6; MYOGLOBIN; MYOSIN; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CYTOPLASM; DNA BINDING; EXOME; FEMALE; FOLLOW UP; FROZEN SECTION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MALE; MIDDLE AGED; MUSCLE DEVELOPMENT; MUSCLE GROWTH; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SEQUENCE HOMOLOGY; SPINDLE CELL; SPINDLE CELL RHABDOMYOSARCOMA; TRANSACTIVATION; VERY ELDERLY; YOUNG ADULT;

EID: 84892399017     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4307     Document Type: Article

References (20)

1. Nascimento AF, Barr FG,. Spindle cell/Sclerosing rhabdomyosarcoma. In WHO Classification of Tumours of Soft Tissue and Bone, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, (eds). IARC: Lyons, 2013; 134-135.
2. Sorensen PH, Lynch JC, Qualman SJ, et al., PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20: 2672-2679.
3. Kikuchi K, Rubin BP, Keller C,. Developmental origins of fusion-negative rhabdomyosarcomas. Curr Top Dev Biol 2011; 96: 33-56.
4. Parham DM, Barr FG,. Alveolar rhabdomyosarcoma. In WHO Classification of Tumours of Soft Tissue and Bone, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, (eds). IARC: Lion, 2013; 130-132.
5. Williamson D, Missiaglia E, de Reynies A, et al., Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-2158.
6. Davicioni E, Anderson MJ, Finckenstein FG, et al., Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009; 174: 550-564.
7. Parham DM, Barr FG,. Embryonal rhabdomyosarcoma. In WHO Classification of Tumours of Soft Tissue and Bone, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, (eds). IARC: Lyons, 2013; 127-129.
8. Mosquera JM, Sboner A, Zhang L, et al., Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 2013; 52: 538-550.
9. de Jong D, Verbeke SL, Meijer D, et al., Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes 2011; 4: 1.
10. Schwarz JM, Rodelsperger C, Schuelke M, et al., MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
11. Cavazzana AO, Schmidt D, Ninfo V, et al., Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol 1992; 16: 229-235.
12. Leuschner I, Newton WA Jr, Schmidt D, et al., Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol 1993; 17: 221-230.
13. Rubin BP, Hasserjian RP, Singer S, et al., Spindle cell rhabdomyosarcoma (so-called) in adults: report of two cases with emphasis on differential diagnosis. Am J Surg Pathol 1998; 22: 459-464.
14. Nascimento AF, Fletcher CDM,. Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol 2005; 29: 1106-1113.
15. Mentzel T, Kuhnen C,. Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases. Virchows Arch 2006; 449: 554-560.
16. Stock N, Chibon F, Binh MB, et al., Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of three morphologic patterns and prognosis. Am J Surg Pathol 2009; 33: 1850-1859.
17. Van Antwerp ME, Chen DG, Chang C, et al., A point mutation in the MyoD basic domain imparts c-Myc-like properties. Proc Natl Acad Sci USA 1992; 89: 9010-9014.
18. Anand G, Shapiro DN, Dickman PS, et al., Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors. J Clin Invest 1994; 93: 5-9.
19. Kuroda K, Tani S, Tamura K, et al., Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem 1999; 274: 7238-7244.
20. Yang Z, MacQuarrie KL, Analau E, et al., MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev 2009; 23: 694-707.